Table 5.
Studies about NOACs vs. warfarin in patients with VTE
| First author (year) |
Design | N of pts | Anticoagulant | Comparator | Recurrent VTE and VTE-related death | Risk of ICH |
|---|---|---|---|---|---|---|
|
Schulman [93] (2009) |
Randomized trial | 2564 | Dabigatran | Warfarin | 2.4% vs. 2.1%, HR 1.10 (0.65–1.84) | 0 vs. 3 |
|
Buller [94] (2012) |
Randomized trial | 4832 | Rivaroxaban | Enoxaparin, followed by warfarin | 2.1% vs. 1.8%, HR 1.12 (0.75–1.68) | 3 vs. 12 |
|
Agnelli [95] (2013) |
Randomized trial | 5395 | Apixaban | Enoxaparin, followed by warfarin | 2.3% vs. 2.7%, HR 0.84 (0.60–1.18) | 3 vs. 6 |
|
Buller [96] (2013) |
Randomized trial | 4921 | Edoxaban | Warfarin | 3.2% vs. 3.5%, HR 0.89 (0.70–1.13) | 0 vs. 6 |
|
Lamsam [97] (2018) |
Retrospective | 218,620 | NOACs | Warfarin | Not mentioned | 1/1000 vs. 3.3/1000 (P < 0.0001) |
N of pts number of patients; NOACs novel oral anticoagulants; HR hazard ratio